UK Medical Device Regulatory Reform Roadmap: What Is Actually Law

1. Key takeaways

The modernisation of UK device regulation is advancing along three tracks: ① long-term recognition of CE marking (policy confirmed on 21 October 2026, pending secondary legislation); ② UKCA modernisation (updating UKCA requirements through a pre-market statutory instrument); and ③ a future licencing route (requiring authorisation through primary legislation, aimed at software and AI devices). As of 29 October 2026, no statutory instruments for tracks ② and ③ have any text in force that can be cited, and current obligations remain governed by the current text of SI 2002/618.

The distinction between the three tracks is not academic. Only the first track has reached the stage of a confirmed government decision, and even that decision still requires the legal mechanics of a statutory instrument before it changes any duty. The other two tracks exist at present as policy direction and legislative intent, described in official publications but not yet drafted into binding law. For planning purposes, this means that every calendar in the compliance system — registration, fees, PMS reporting, vigilance — should continue to run on the current regulations without modification, while the reform documents are tracked separately as forward-looking intelligence rather than as a source of current requirements.

2. Legal basis

• Text currently in force: UK MDR 2002 (SI 2002/618, as amended).
• GOV.UK news announcement — Government confirms indefinite recognition of CE marked medical devices (21 October 2026): states that the UKCA route is being modernised through a pre-market statutory instrument, and that primary legislation will be sought to provide authorisation for developing a future licencing route.
• GOV.UK consultation response — Medical devices regulations: targeted consultation on the indefinite recognition of CE marked devices (published 21 October 2026).
• MHRA 2030 Strategy (published 14 October 2026).

3. Expert insights

Insight one: the three legal instruments sit at different levels and therefore land at different speeds. Secondary legislation (a statutory instrument) amending UK MDR 2002 can deliver both the long-term recognition of CE marking and UKCA modernisation; the future licencing route, by contrast, requires authorisation through primary legislation, a longer procedure with higher uncertainty. Distinguishing the level of each instrument is the first step in judging how credible any timetable is. Announcements about instruments that still need Parliament’s attention should be discounted accordingly, whereas an instrument that has completed its parliamentary stages carries a real date.

Insight two: the reform content points to structural change. According to public information, the direction of the pre-market statutory instrument includes international mutual recognition (Australia, Canada, the United States), mandatory UDI, alignment of IVD classification with the IMDRF A/B/C/D scheme, implant cards, strengthened technical documentation requirements, traceability for custom-made devices, and removal of the physical UKCA mark requirement conditional on the UDI having been assigned and being publicly searchable. Once these items land, they will change companies’ documentation and labelling systems. Label artwork, IFU references, and technical file structure are all touched, which is why the lead time for implementation is measured in redesign cycles rather than in weeks.

Insight three: the lag between policy and law must be managed explicitly. The announcement of 21 October 2026 is a policy confirmation, and the official announcement itself notes that engagement with patients, clinicians and industry will continue as implementation is advanced. Before the legislation takes effect, no claim that the new rules are already in force is valid. Marketing or commercial teams that communicate reform intentions as current obligations create regulatory and contractual exposure that is entirely avoidable through a simple internal rule: only the current text of SI 2002/618 governs today’s compliance statements.

Insight four: the announcement also carries a governance signal worth reading. The GOV.UK documents listed above were published on the same day as the MHRA 2030 Strategy, and the consultation response on indefinite recognition was issued alongside the government announcement confirming it. Publishing the policy decision, the consultation response and the strategy together indicates a coordinated programme rather than isolated moves, which in turn suggests that the pre-market statutory instrument is being prepared on a serious timetable. The practical reading for manufacturers is not to predict dates, but to recognise that the direction is set at government level and that internal budgets for labelling, UDI and documentation work can be reserved now on a contingent basis, to be activated only when the in-force stage arrives.

4. Practical recommendations

GRZAN recommends that clients maintain a UK regulatory change monitoring ledger, tracking each measure through four stages — policy confirmation / draft notified / laid before Parliament / in force — and marking at each stage whether business arrangements may be adjusted on that basis: adjustment is permissible only at the in-force stage. For the proposed content, low-cost preparation can be undertaken (for example, organising technical summaries and completing UDI selection), but the current compliance route must not be changed. As a practical estimate, the ledger earns its keep when it names an owner for each tracked item and records the date of each observed change, because reform narratives tend to circulate inside organisations faster than they can be verified, and an unverified rumour repeated in a customer audit is far more expensive than the monitoring itself. Quarterly reviews of the ledger, aligned to MHRA publication cycles, are sufficient to keep it current without becoming a full-time task.

5. Verification checklist

• □ The three levels of policy confirmation, draft and in force have been distinguished
• □ Current compliance arrangements remain based on the current text of SI 2002/618
• □ A regulatory change monitoring ledger and a responsible owner have been established
• □ Low-cost preparation has been completed (technical summaries, UDI selection)
• □ External materials do not present legislative intention as current obligation

Regulatory information verified as of 29 October 2026.

• Appointment of the UK Responsible Person (UKRP) and support with signing the letter of authorisation
• Full-process MHRA registration (DORS) filing and account lifecycle management
• Device classification determination, GMDN code selection and annual registration fee calculation
• Dual-route design for Great Britain and Northern Ireland, including UK(NI) solutions
• Establishment of post-market surveillance (PMS) systems, preparation of PMSR/PSUR and submission of vigilance reports
• Emergency handling of serious adverse incidents and field safety corrective actions (FSCA)
• Monitoring of UK regulatory changes and compliance gap assessment

For post-market compliance support in the UK market — vigilance reporting, recall management and MHRA inspection response — contact GRZAN at info@grzanglobal.com.